ABBV-744 AS A POTENTIAL THERAPEUTIC OPTION FOR AGGRESSIVE CANCERS SECRETS

In Segment C, participants will obtain ABBV-744 and oral navitoclax. In Section D, participants will get ABBV-744 and ruxolitinib. Members will acquire treatment right until illness progression or even the members are unable to tolerate the study drugs.88 These preclinical studies present paradigms for future clinical trials in AML, and the use of